← All trials
NCT05693272
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2023
- Primary completion
- May 30, 2024
- Completion date
- May 30, 2024
- First posted
- Jan 20, 2023
- Last posted
- Jun 2, 2023
- Enrollment
- 47
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of SaskatchewanLead sponsor
- University of SaskatchewanReponsible party - principal investigator
- Government of CanadaCollaborator
- Government of SaskatchewanCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.